ROBOZ, GJ, H DOHNER, C POCOCK, H DOMBRET, F RAVANDI, JH JANG, D SELLESLAG, Jiří MAYER, UM MARTENS, J LIESVELD, T BERNAL, MC WANG, PW YU, L SHI, S GUO, Torre I LA, B SKIKNE, Q DONG, J BRAVERMAN, SA NEHME, CL BEACH and AH WEI. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, vol. 106, No 12, p. 3240-3244. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.279174.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
Authors ROBOZ, GJ, H DOHNER, C POCOCK, H DOMBRET, F RAVANDI, JH JANG, D SELLESLAG, Jiří MAYER, UM MARTENS, J LIESVELD, T BERNAL, MC WANG, PW YU, L SHI, S GUO, Torre I LA, B SKIKNE, Q DONG, J BRAVERMAN, SA NEHME, CL BEACH and AH WEI.
Edition haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2021, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 11.047
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2021.279174
UT WoS 000732456400031
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 4/1/2022 13:15.
PrintDisplayed: 24/7/2024 15:17